Get the Stockscreener App
9.79
3.71%
0.35
Satellos Bioscience Inc stock is traded at $9.79, with a volume of 165.79K.
It is up +3.71% in the last 24 hours and up +66.50% over the past month.
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.
See More
Previous Close:
$9.44
Open:
$9.34
24h Volume:
165.79K
Relative Volume:
3.13
Market Cap:
$203.94M
Revenue:
-
Net Income/Loss:
$-28.50M
P/E Ratio:
-5.4005
EPS:
-1.8128
Net Cash Flow:
$-25.87M
1W Performance:
+31.94%
1M Performance:
+66.50%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$9.34
$10.00
1-Week Range:
$7.32
$10.00
52-Week Range:
$5.44
$13.39
Satellos Bioscience Inc Stock (MSLE) Company Profile
Name
Satellos Bioscience Inc
Sector
Industry
Phone
-
Address
-
Compare MSLE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MSLE
Satellos Bioscience Inc
|
9.79 | 203.94M | 0 | -28.50M | -25.87M | -1.8128 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Satellos Bioscience Inc Stock (MSLE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-06-26 | Initiated | Leerink Partners | Outperform |
| Mar-11-26 | Initiated | Cantor Fitzgerald | Overweight |
Satellos Bioscience Inc Stock (MSLE) Latest News
Satellos Bioscience Inc.Common Stock (MSLE) Stock Price, News, Quote & History - FinancialContent
Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update - TradingView
Satellos Bioscience Delivers Promising DMD Data With Fast Track Win - Streetwise Reports
Why Satellos Bioscience Inc. stock is skyrocketing today - Wealth Awesome
H.C. Wainwright Maintains Satellos Bioscience(MSLE.US) With Buy Rating, Raises Target Price to $18 - Moomoo
Satellos Bioscience stock price target raised to $18 by H.C. Wainwright on trial data By Investing.com - Investing.com India
Satellos Bioscience stock price target raised to $18 by H.C. Wainwright on trial data - Investing.com South Africa
Satellos reports six-month Phase II data for SAT-3247 in Duchenne muscular dystrophy - The Pharma Letter
HC Wainwright Forecasts Strong Price Appreciation for Satellos Bioscience (NASDAQ:MSLE) Stock - MarketBeat
MSLE Maintained by HC Wainwright & Co. -- Price Target Raised to $18.00 - GuruFocus
Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247 - Investing News Network
Phase II DMD Trailhead data hike Satellos’ stock - BioWorld News
Satellos Bioscience's Share Rise After SAT-3247 Shows Positive Results for Duchenne MD - Moomoo
Satellos reports positive TRAILHEAD data for DMD drug - grafa.com
Why Is Satellos Bioscience Trading Higher Today?Satellos Bioscience (NASDAQ:MSLE) - Benzinga
Satellos Bioscience Posts Encouraging Six-Month TRAILHEAD Data in Adult DMD Patients - TipRanks
[6-K] Satellos Bioscience Inc. Current Report (Foreign Issuer) | MSLE SEC FilingForm 6-K - Stock Titan
Satellos Reports Six-Month Interim TRAILHEAD Data Showing - GlobeNewswire
Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence - Sahm
Why Satellos Bioscience Inc. stock is sliding today - Wealth Awesome
If You Invested $1,000 in Satellos Bioscience Inc (MSCLF) - Stock Titan
Why Satellos Bioscience Inc. stock is rising today - Wealth Awesome
Drug Developer Scores Major FDA Nod, Eyes Big Gains in Muscle Disease Market - Streetwise Reports
Why Satellos Bioscience Inc. stock is plummeting today - Wealth Awesome
Satellos Bioscience Ord Shs (MSLE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Guggenheim Maintains Satellos Bioscience(MSLE.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Satellos gets FDA Fast Track for SAT-3247 - grafa.com
Satellos Bioscience up near 10% as SAT-3247 Granted FDA Fast Track Designation - marketscreener.com
Stocks in play: Satellos Bioscience Inc. - The Globe and Mail
Satellos Bioscience Shares Climb After FDA Fast Track Designation - Moomoo
Fast Track Designation for Satellos' SAT-3247 (MSLE) in Duchenne Treatment - GuruFocus
Satellos Wins FDA Fast Track Status for Duchenne Drug SAT-3247 - TipRanks
Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy - The Manila Times
FDA Fast Track boosts Satellos (NASDAQ: MSLE) SAT-3247 Duchenne program - Stock Titan
Satellos wins FDA Fast Track for Duchenne drug SAT-3247 - Stock Titan
Price to sales forward of Satellos Bioscience Inc – TSX:MSCL - TradingView
Satellos Bioscience Inc Actuals & Estimates (DUS:0IT) - TradingView
Price to earnings forward of Satellos Bioscience Inc – TSX:MSCL - TradingView
EBITDA margin % of Satellos Bioscience Inc – DUS:0IT - TradingView
Price to earnings forward of Satellos Bioscience Inc – DUS:0IT - TradingView
Enterprise value to revenue forward of Satellos Bioscience Inc – DUS:0IT - TradingView
Operating margin % of Satellos Bioscience Inc – DUS:0IT - TradingView
Satellos Bioscience Inc Statistics – DUS:0IT - TradingView
0IT Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Satellos Bioscience Inc – FWB:0IT - TradingView
Price to book forward of Satellos Bioscience Inc – FWB:0IT - TradingView
Price to earnings forward of Satellos Bioscience Inc – FWB:0IT - TradingView
Enterprise value to EBIT forward of Satellos Bioscience Inc – FWB:0IT - TradingView
Satellos Bioscience Inc Actuals & Estimates (TSX:MSCL) - TradingView
Satellos Bioscience Inc Actuals & Estimates (FWB:0IT) - TradingView
Satellos to Present Clinical Program Updates at ICNMD 2026 - Investing News Network
Satellos Bioscience Inc Stock (MSLE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):